PROs Affirm Zongertinib’s Combination of Strong Response Rates With Low Toxicity
Published: | Updated:
Zongertinib shows promising results in HER2-mutant NSCLC, offering high response rates and improved quality of life with minimal toxicity.
Joshua K. Sabari, MD
Advertisement
Articles by Joshua K. Sabari, MD
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs
2
Oral COVID-19 PEP May Benefit High-Risk Groups More Than General Public: Peter J. Hotez, MD
3
Walcker Named President of Cardinal’s The Specialty Alliance, With Strengths in GI, Urology
4
Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV
5